Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of BLI400 in chronic constipation
NCT02819310Phase 3Completed
- Sponsor
- Braintree Laboratories
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lactitol in chronic idiopathic constipation (CIC), sponsored by Braintree Laboratories. Primary endpoint: Treatment Emergent Adverse Events at 12 months. Started Jun 2016; status: completed.
02
Drugs
lactitol
03
Conditions
chronic idiopathic constipation (CIC)
Beyond the preview
Go deeper on NCT02819310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819310.